Bronchiectasis and macrolides [3];Bronquiectasias y macrólidos

Archivos de Bronconeumologia

Volumn 42, Issue 4, 2006, Pages 206-

  Vila Justribo, M ^a   Dorca Sargatal, J ^b   Bello Dronda, S ^c  

^a HOSPITAL ARNAU DE VILANOVA   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; AZITHROMYCIN; IMMUNOMODULATING AGENT; MACROLIDE;

BACTERIAL COLONIZATION; BRONCHIECTASIS; HUMAN; IN VITRO STUDY; LETTER; PSEUDOMONAS AERUGINOSA;

EID: 33646509882     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13086629     Document Type: Letter

References (6)

1. Máiz Cairo L. Tratamiento con azitromicina a largo plazo en un paciente con bronquiectasias idiopáticas. Arch Bronconeumol. 2005;41:295-6.
2. Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol. 2001;31:464-73.
3. Oligaki N. Bacterial biofilm in chronic airway infection. Kasenshogaku Zasshi. 1994;68:138-51.
4. Amsden GW. Anti-inflammatory effects of macrolides - an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother. 2005;55:10-21.
5. Rubin BK, Henke MO. Immunomodulatory activity and effectiveness of macrolides in chronic airway disease. Chest. 2004;125:70-8.
6. Scheinberg P, Shore E, on behalf of the PC-TNDS-008 Study Group. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest. 2005;127:1420-6.